#PNH
-
News
EHA2023 | Crovalimab Appears Non-inferior to Eculizumab in PNH, Data Shows
At the 2023 EHA Congress, researchers presented data from the ongoing COMMODORE 2 study, which was designed to determine whether crovalimab is non-inferior to eculizumab for multiple clinical endpoints among…
Read More » -
News
EHA2023 | MASP-3 Inhibitor Demonstrates Clinical Efficacy in Paroxysmal Nocturnal Hemoglobinuria
OMS906 led to transfusion independence in the majority of patients with PNH enrolled so far on the trial (n = 10). PNH, a rare and life-threatening blood disorder, is characterized…
Read More » -
News
CLINICAL NEWS | Novartis Releases Data for Potentially “Practice-Changing” PNH Medicine
The results, announced via news release, were presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation in Paris. “The APPOINT-PNH results are consistent with…
Read More » -
News
CLINICAL RESULTS | Roche Reports Positive Data For Crovalimab As Rare Blood Disease Treatment
PNH causes a patient’s red blood cells to break apart, resulting in a range of debilitating symptoms such as anaemia, fatigue, blood clots and kidney disease. The treatment is for…
Read More » -
News
NEW APPROVAL | Health Canada Grants Approval To Sobi’s PNH Therapy
The treatment is indicated for such patients with insufficient response to, or are not tolerant to, a C5 inhibitor. The latest development is based on the findings from the head-to-head…
Read More » -
News
CLINICAL UPDATE | Novartis Builds Case For Iptacopan As Oral Rival To PNH Injectables
On December 8, the Swiss pharma group announced that the top-line results of the APPOINT-PNH clinical trial showed that iptacopan provided “clinically meaningful” increases in haemoglobin levels in patients with…
Read More » -
News
CLINICAL NEWS | First Cohort of Patients Dosed In Phase 2 Study Of KP104 In PNH
KP104 is a first-in-class, bifunctional biologic designed to modulate complement activity through selective targeting of key intervention points in the alternative and terminal complement pathways. On July 28, 2022, the…
Read More »